Using math models to improve treatment for serious drug‑resistant lung infections
Core 3 Math Modeling Core
['FUNDING_P01'] · UNIVERSITY OF FLORIDA · NIH-11164500
Researchers are using mathematical models to design better antibiotic plans for people with ventilator‑associated pneumonia from carbapenem‑resistant Acinetobacter and Klebsiella.
Quick facts
| Phase | ['FUNDING_P01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF FLORIDA (nih funded) |
| Locations | 1 site (GAINESVILLE, UNITED STATES) |
| Trial ID | NIH-11164500 on ClinicalTrials.gov |
What this research studies
If I or a loved one had ventilator‑associated pneumonia from a drug‑resistant bug, this team would use detailed math models to help choose antibiotic combinations and dosing that kill bacteria and limit resistance. The core builds high‑dimensional models from lab data including penicillin‑binding protein occupancy and mechanistic assays. It will integrate data on β‑lactams, β‑lactamase inhibitors, and high bacterial densities from connected projects to simulate treatment outcomes. The models are intended to guide more effective treatment plans for these severe infections.
Who could benefit from this research
Good fit: Patients with ventilator‑associated bacterial pneumonia caused by carbapenem‑resistant Acinetobacter baumannii or carbapenem‑resistant Klebsiella pneumoniae, especially those treated in hospital intensive care units.
Not a fit: People with mild infections, infections caused by drug‑sensitive organisms, or non‑respiratory infections are unlikely to receive direct benefit from this specific work.
Why it matters
Potential benefit: Could lead to antibiotic regimens that clear infections faster and reduce the chance that bacteria develop or carry on drug resistance.
How similar studies have performed: Prior mathematical modeling has helped optimize antibiotic dosing in lab and animal settings and informed clinical decisions, but applying these models to high‑density, carbapenem‑resistant ventilator‑associated pneumonia is relatively new.
Where this research is happening
GAINESVILLE, UNITED STATES
- UNIVERSITY OF FLORIDA — GAINESVILLE, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: NEELY, MICHAEL N. — UNIVERSITY OF FLORIDA
- Study coordinator: NEELY, MICHAEL N.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.